Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 557 participants.
Also called NCT01758380
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 557 participants
- Sponsor
- Registry
-
NCT01758380 -
2011-005499-41
-
- Other papers using this trial's data
- A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Denmark, Egypt, Germany, Indonesia, Jordan, Kuwait, Lebanon, Malaysia, Russia, Saudi Arabia, Singapore, Spain, Tunisia, Türkiye, United Arab Emirates, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01758380. Randomized; quadruple masking; primary purpose treatment. Start 2013-01 (registry gives no type); primary completion 2013-09 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan
- Acronym
- STEADFAST
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Vildagliptin
- Intervention (Drug)
- Gliclazide
- Intervention (Drug)
- Metformin
- Intervention (Drug)
- Placebo to Gliclazide
- Intervention (Drug)
- Placebo to Vildagliptin
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct01758380- Content hash
2ee90b6228226fa5962b3e2ebc35a37f18bb9fdc79708895b85ab04b177332f7